Table 3.

Effects of treatment of ErPCs from homozygous β⁰39-thalassemic patients on hemoglobin production

Genotype	Hemoglobin	(−)	T9W	MTH	T9W + MTH
β039/β039	HbF	51.99	44.06	61.91	58.40
	α-peak	16.91	7.61	7.37	2.32
	HbA	3.29	24.01	2.9	21.45
	HbA2	27.64	24.27	27.80	17.79
β039/β039	HbF	32.43	29.93	51.05	43.31
	α-peak	35.37	30.65	24.19	19.15
	HbA	0.46	10.93	0.32	14.98
	HbA2	31.12	27.91	24.09	22.14
β039/β039	HbF	34.68	28.21	45.34	31.06
	α-peak	28.03	18.33	23.01	15.72
	HbA	0.63	23.05	0.44	25.15
	HbA2	36.35	29.85	30.33	27.56
β039/β039	HbF	25.19	19.91	60.01	53.13
	α-peak	11.31	5.78	6.12	2.37
	HbA	3.64	24.42	2.65	17.42
	HbA2	59.70	49.33	30.45	26.96
β039/β039	HbF	48.41	31.74	67.77	40.44
	α-peak	25.91	8.26	14.82	5.91
	HbA	1.05	44.71	1.84	41.47
	HbA2	23.99	14.93	15.39	11.79

Data represent the percent of the indicated hemoglobins (HbF, HbA, and HbA₂). The α peak has been identified as a HPLC peak containing α-globin. T9W was used at MOI generating an average of one integration/genome. MTH was used at 50 nM